Markets News

Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.

Gold Miners Tumble 4.6% as Warsh's Hawkish Stance Jolts August Rally
Markets Daniel Marsh

Gold Miners Tumble 4.6% as Warsh's Hawkish Stance Jolts August Rally

Gold miners dropped 4.6% after Fed Chair Warsh signaled more rate hikes, erasing part of August's 23.8% surge. Junior miners fell 5.14%, while Newmont's margin cushions losses.

GDX GDXJ GLD NEM
Staffing Stocks Surge 39% in August as Temp Hiring Jumps 4.4%
Markets Daniel Marsh

Staffing Stocks Surge 39% in August as Temp Hiring Jumps 4.4%

U.S. staffing stocks jumped 39% in August as temp hiring grew 4.4%, with Kelly Services, TrueBlue, AMN Healthcare, and ManpowerGroup posting triple-digit gains.

KELYA TBI AMN MAN
Treasury Yields Jump as Warsh Signals September Rate Hike
Markets Daniel Marsh

Treasury Yields Jump as Warsh Signals September Rate Hike

Two-year Treasury yield jumps 9.5 bps to 4.325% as Fed Chair Warsh's inflation comments lift September rate hike odds to 55.7%. 10-year yield rises to 4.70%.

Femasys Soars 15% as UNC Health Adopts Fertility Tech Across Clinics
Markets Daniel Marsh

Femasys Soars 15% as UNC Health Adopts Fertility Tech Across Clinics

Femasys shares surged 15% after UNC Health agreed to deploy FemaSeed fertility products across its OB/GYN clinics, boosting investor confidence despite weak quarterly sales.

FEMY
Rivian CFO Exit Sparks 6.5% Stock Drop Amid R2 Ramp-Up
Markets Daniel Marsh

Rivian CFO Exit Sparks 6.5% Stock Drop Amid R2 Ramp-Up

Rivian shares dropped 6.5% after CFO Claire McDonough announced departure, fueling concerns about R2 production ramp-up and cost control. Interim CFO Derek Mulvey appointed.

RIVN
Swvl Soars 34% on $14.5M Funding for U.S. Expansion
Markets Daniel Marsh

Swvl Soars 34% on $14.5M Funding for U.S. Expansion

Swvl (SWVL) shares surged 34% after a $14.5M strategic investment to fund U.S. expansion, with new shares nearly doubling outstanding count.

SWVL
KASE Global Weekend Close: PayPal, Nvidia Tumble as US Shares Reprice
Markets Daniel Marsh

KASE Global Weekend Close: PayPal, Nvidia Tumble as US Shares Reprice

PayPal and Nvidia sink on KASE Global's Friday close, while Microsoft and Amazon advance. Asian benchmarks diverge as Korea's KOSPI falls sharply.

PYPL NVDA QCOM MSFT AMZN GLD TSM SMCI
Investors Pull $22.3B from U.S. Equity Funds in Largest Outflow Since March
Markets Daniel Marsh

Investors Pull $22.3B from U.S. Equity Funds in Largest Outflow Since March

U.S. equity funds posted $22.33B in outflows, the largest since March, as large-cap withdrawals dwarfed small-cap inflows. Bond funds saw $7.12B inflows.

IWM SPY QQQ AGG
Callaway Gains After Cutting Ties with Good Good, Commits $1M
Markets Daniel Marsh

Callaway Gains After Cutting Ties with Good Good, Commits $1M

Callaway shares climbed 2.5% after terminating its Good Good Golf partnership and pledging $1 million to anti-violence groups, a move analysts see as a brand-risk reset.

CALY
Novavax Dips Slightly After Nuvaxovid Gains Approval in US, EU, Japan
Markets Daniel Marsh

Novavax Dips Slightly After Nuvaxovid Gains Approval in US, EU, Japan

Novavax shares slipped 0.6% to $9.00 after regulatory approvals for its updated vaccine in the US, EU, and Japan. The company now relies on partners like Sanofi for commercialization, with royalties expected but not yet in guidance.

NVAX SNY MRNA PFE
SharonAI Tumbles 4.2% as Nvidia Pauses Cloud Financing, Clouding $4.88B Deal
Markets Daniel Marsh

SharonAI Tumbles 4.2% as Nvidia Pauses Cloud Financing, Clouding $4.88B Deal

SharonAI shares dropped 4.2% after Nvidia paused parts of a cloud financing initiative, raising questions about its $4.88 billion compute agreement.

NVDA
Cytokinetics Drops 5% Despite Positive Phase 3 Data in nHCM
Markets Daniel Marsh

Cytokinetics Drops 5% Despite Positive Phase 3 Data in nHCM

Cytokinetics shares slid 5% despite positive Phase 3 trial results for MYQORZO in non-obstructive HCM, as investors hoped for larger clinical benefits.

CYTK